ArticleDrug delivery2018
Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Article in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 110 citations in OpenAlex.
- Destroy and reconstruct: A microneedle platform for combined NIR-II photothermal therapy and asiaticoside-mediated tissue regeneration in cutaneous amyloidosis.Materials today. Bio · 2026Article
- Multifunctional vesicles in cancer therapy and theranostics: current advances and future challenges.Journal of nanobiotechnology · 2025Review
- Nanotechnology-Driven Drug Delivery Systems for Lung Cancer: Computational Advances and Clinical Perspectives.Thoracic cancer · 2025Review
- Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects.Experimental hematology & oncology · 2025Review
- Biological Properties of Arginine-rich Peptides and their Application in Cargo Delivery to Cancer.Current drug delivery · 2025Review
- CRISPR/Cas9 in colorectal cancer: Revolutionizing precision oncology through genome editing and targeted therapeutics.Iranian journal of basic medical sciences · 2025Review
- Development of Curcumin Encapsulated Liposomes in Chlorhexidine-Loaded Organogel Using Ternary Phase Systems for Treatment of Omphalitis in Infants.Advances in pharmacological and pharmaceutical sciences · 2025Article
- Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications.Current oncology (Toronto, Ont.) · 2024Review
- Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands.Journal of nanobiotechnology · 2024Review
- Proteomics identification of overexpressed serum proteins in dogs withVeterinary world · 2023Article
- Recent Preclinical and Clinical Progress in Liposomal Doxorubicin.Pharmaceutics · 2023Review
- Nano-biotechnology in tumour and cancerous disease: A perspective review.Journal of cellular and molecular medicine · 2023Review
- New trends in diagnosing and treating ovarian cancer using nanotechnology.Frontiers in bioengineering and biotechnology · 2023Review
- Article
- Membrane Internalization Mechanisms and Design Strategies of Arginine-Rich Cell-Penetrating Peptides.International journal of molecular sciences · 2022Review
- Evaluation of the Biodistribution of Arginine, glycine, aspartic acid peptide-modified Nanoliposomes Containing Curcumin in Rats.Iranian journal of biotechnology · 2022Article
- Sequential Drug Delivery in Targeted Cancer Therapy.Pharmaceutics · 2022Review
- Increased Targeting Area in Tumors by Dual-Ligand Modification of Liposomes with RGD and TAT Peptides.Pharmaceutics · 2022Article
- Functionalized Liposome and Albumin-Based Systems as Carriers for Poorly Water-Soluble Anticancer Drugs: An Updated Review.Biomedicines · 2022Review
- Do Lipid-based Nanoparticles Hold Promise for Advancing the Clinical Translation of Anticancer Alkaloids?Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Off-target effects of drugs severely limit cancer therapy. Targeted nanocarriers are promising to enhance the delivery of therapeutics to tumors. Among many approaches for active tumor-targeting, arginine-rich cell penetrating peptides (AR-CPP) and ligands specific to target over-expressed receptors on cancer-cell surfaces, are popular. Earlier, we showed that the attachment of an AR-CPP octaarginine (R8) to the surface of DOXIL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.